Metagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt Fund
• Metagenomi is a genomic medicines company pioneering precision gene editing systems to advance curative therapies for oncology and genetic diseases • Proprietary and wholly owned gene editing platform offers the potential to expand the range of treatable diseases and to improve patient